Answer
No, teclistamab-mediated killing of BCMA-positive cells occurs independently of T-cell receptor specificity and without reliance on MHC class I molecules on antigen-presenting cells.
Sources for this answer
- TECVAYLI 90mg/ml solution for injectionJanssen-Cilag Ltd (a Johnson & Johnson Company) · emc · SmPC §5.1 Pharmacodynamic properties · Version 11Document updated
Sources checked